Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Chuikyo OKs NHI Price Listing of SGLT-2 Inhibitors, New Point-Based Calculations Adopted from This Time
May 15, 2014
-
BUSINESS Santen Acquires Merck’s Eye Drugs in Japan, Key Markets
May 14, 2014
-
REGULATORY PIC/S to Discuss Japan’s Accession at Upcoming Meeting in Rome; MHLW Anticipates Formal Approval
May 14, 2014
-
BUSINESS 4 Major Wholesalers’ Average Operating Margin Tops 1% Mark, Signaling Biz Recovery
May 13, 2014
-
BUSINESS Astellas Pres. “Aware” of Rumored Marriage with Daiichi Sankyo, but Denies Any Merger at This Time
May 13, 2014
-
BUSINESS FY2013 Japan Ethical Drug Market Crosses 10 Trillion Yen Mark for 1st Time: IMS
May 12, 2014
-
BUSINESS MTPC to Push Tenelia, Canaglu to Compete in Diabetes Field
May 9, 2014
-
BUSINESS Eisai Moves to Boost Global Use of Products via Emerging Market Businesses
May 8, 2014
-
REGULATORY Pilot Program for Compassionate Access System Gets Underway with Sanofi’s Cabazitaxel
May 7, 2014
-
REGULATORY Joint Panel of Health, Science Ministries Wraps Up Talks on Ethics Code for Epidemiological, Clinical Research
May 2, 2014
-
REGULATORY Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
-
BUSINESS Takeda, Teva to Commercialize Teva’s Parkinson’s Disease Treatment Rasagiline in Japan
April 30, 2014
-
ACADEMIA Chiba University to Advise Researchers to Retract Diovan Papers
April 28, 2014
-
REGULATORY MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
-
REGULATORY Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
-
BUSINESS MTPC Names Masayuki Mitsuka as New President
April 24, 2014
-
BUSINESS Astellas Aims to Dominate SGLT-2 Inhibitor Market with Suglat
April 23, 2014
-
BUSINESS Lilly Japan Starts PIII Study of Tadalafil for DMD Treatment
April 22, 2014
-
REGULATORY MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
-
REGULATORY New Health Ministry Panel to Compile Report on Clinical Research Regulations by Autumn
April 18, 2014
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…